81 related articles for article (PubMed ID: 3198216)
21. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.
Bedford P; Fichtinger-Schepman AM; Shellard SA; Walker MC; Masters JR; Hill BT
Cancer Res; 1988 Jun; 48(11):3019-24. PubMed ID: 3365691
[TBL] [Abstract][Full Text] [Related]
22. The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: comparison of immunocytochemical determination with detection in isolated DNA.
Blommaert FA; Floot BG; van Dijk-Knijnenburg HC; Berends F; Baan RA; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
Chem Biol Interact; 1998 Jan; 108(3):209-25. PubMed ID: 9528691
[TBL] [Abstract][Full Text] [Related]
23. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells.
Blommaert FA; van Dijk-Knijnenburg HC; Dijt FJ; den Engelse L; Baan RA; Berends F; Fichtinger-Schepman AM
Biochemistry; 1995 Jul; 34(26):8474-80. PubMed ID: 7599137
[TBL] [Abstract][Full Text] [Related]
24. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair.
Chao CC
Mol Pharmacol; 1994 Jun; 45(6):1137-44. PubMed ID: 8022407
[TBL] [Abstract][Full Text] [Related]
25. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
26. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
Lippert B
Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842
[TBL] [Abstract][Full Text] [Related]
27. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
Fisch MJ; Howard KL; Einhorn LH; Sledge GW
Clin Cancer Res; 1996 Jun; 2(6):1063-6. PubMed ID: 9816268
[TBL] [Abstract][Full Text] [Related]
28. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
[TBL] [Abstract][Full Text] [Related]
30. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
31. Formation and differential repair of covalent DNA adducts generated by treatment of human cells with (+/-)-anti-dibenzo[a,l]pyrene-11,12-diol-13,14-epoxide.
Spencer WA; Singh J; Orren DK
Chem Res Toxicol; 2009 Jan; 22(1):81-9. PubMed ID: 19053321
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo.
Rothbarth J; Koevoets C; Tollenaar RA; Tilby MJ; van de Velde CJ; Mulder GJ; Kuppen PJ
Biochem Pharmacol; 2004 May; 67(9):1771-8. PubMed ID: 15081876
[TBL] [Abstract][Full Text] [Related]
33. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
Roberts JJ; Friedlos F
Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
[TBL] [Abstract][Full Text] [Related]
34. Benzo(a)pyrene-DNA adduct formation and removal in mouse epidermis in vivo and in vitro: relationship of DNA binding to initiation of skin carcinogenesis.
Nakayama J; Yuspa SH; Poirier MC
Cancer Res; 1984 Sep; 44(9):4087-95. PubMed ID: 6331664
[TBL] [Abstract][Full Text] [Related]
35. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
36. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
[TBL] [Abstract][Full Text] [Related]
37. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
Reed E; Litterst CL; Thill CC; Yuspa SH; Poirier MC
Cancer Res; 1987 Feb; 47(3):718-22. PubMed ID: 3802077
[TBL] [Abstract][Full Text] [Related]
38. Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells.
Tacka KA; Szalda D; Souid AK; Goodisman J; Dabrowiak JC
Chem Res Toxicol; 2004 Nov; 17(11):1434-44. PubMed ID: 15540941
[TBL] [Abstract][Full Text] [Related]
39. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
Evans DL; Tilby M; Dive C
Cancer Res; 1994 Mar; 54(6):1596-603. PubMed ID: 8137265
[TBL] [Abstract][Full Text] [Related]
40. Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding.
Fichtinger-Schepman AM; Baan RA; Luiten-Schuite A; van Dijk M; Lohman PH
Chem Biol Interact; 1985 Nov; 55(3):275-88. PubMed ID: 4075437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
